Allelic and locus heterogeneity in inherited venous malformations.

Venous malformations are low-flow vascular lesions consisting of disorganized thin-walled vascular channels. These can occur sporadically but also as an autosomal dominant condition termed venous malformations, cutaneous and mucosal (VMCM; OMIM 600195). In two large unrelated kindreds mapping to chromosome 9, the identical R849W missense mutation was identified in the first kinase domain of Tie2, an endothelial cell-specific receptor tyrosine kinase. We report here the identification of four new kindreds with inherited venous malformations. Unlike the initial two families described, these four families demonstrate allelic and locus heterogeneity. In one of these families, the R849W mutation co-segregates with the disease phenotype. Three other families with venous malformations lack this mutation. One of these families is linked to markers near TIE2 on chromosome 9. In this family, we identified a novel mutation within the first kinase domain of Tie2 resulting in a Y897S change. Results from COS-1 cell transfections using expression constructs containing either the R849W or the Y897S mutation suggest that the receptors containing either mutation show ligand-independent hyperphosphorylation. These results suggest a gain-of-function mechanism for development of venous malformations in these families. Of the two remaining families, one excludes linkage to the TIE2 locus, establishing the existence of at least one additional locus for dominantly inherited venous malformations.

[1]  P. Rao,et al.  Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. , 1998, British Journal of Cancer.

[2]  M. Dewhirst,et al.  Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. , 1997, Circulation research.

[3]  R. Erickson,et al.  FamiIial vascuIar malformations Report of 25 members of one family , 1984, Clinical genetics.

[4]  J. York,et al.  Tyrosine 1101 of Tie2 Is the Major Site of Association of p85 and Is Required for Activation of Phosphatidylinositol 3-Kinase and Akt , 1998, Molecular and Cellular Biology.

[5]  J. Massagué,et al.  Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. , 1999, Nature.

[6]  L. Cantley,et al.  Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. , 1997, Science.

[7]  J. Partanen,et al.  Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization. , 1992, Blood.

[8]  H. Schnürch,et al.  Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. , 1993, Development.

[9]  M. Dewhirst,et al.  Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Mulliken,et al.  Vascular Birthmarks: Hemangiomas and Malformations , 1988 .

[11]  K. Alitalo,et al.  Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response , 1999, Oncogene.

[12]  D. Ornitz,et al.  Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia , 1996, Nature Genetics.

[13]  D. W. Johnson,et al.  A gene for familial venous malformations maps to chromosome 9p in a second large kindred. , 1995, Journal of medical genetics.

[14]  Thomas N. Sato,et al.  Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.

[15]  C. Birchmeier,et al.  Multiple essential functions of neuregulin in development , 1995, Nature.

[16]  J. Seidman,et al.  Assignment of a locus for dominantly inherited venous malformations to chromosome 9p. , 1994, Human molecular genetics.

[17]  Gary R. Grotendorst,et al.  Attachment of smooth muscle cells to collagen and their migration toward platelet-derived growth factor. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Rao,et al.  GRB2 and SH-PTP2: potentially important endothelial signaling molecules downstream of the TEK/TIE2 receptor tyrosine kinase. , 1995, Oncogene.

[19]  J. Rossant,et al.  tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. , 1992, Oncogene.

[20]  S. Ziegler,et al.  Molecular cloning and characterization of a novel receptor protein tyrosine kinase from human placenta. , 1993, Oncogene.

[21]  P. Marsden,et al.  Endothelial Tie2/Tek ligands angiopoietin-1 (ANGPT1) and angiopoietin-2 (ANGPT2): regional localization of the human genes to 8q22.3-q23 and 8p23. , 1998, Genomics.

[22]  M. Dewhirst,et al.  Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. , 1997, The Journal of clinical investigation.

[23]  L. Cantley,et al.  Vascular Dysmorphogenesis Caused by an Activating Mutation in the Receptor Tyrosine Kinase TIE2 , 1996, Cell.

[24]  D. Dumont,et al.  The Tek/Tie2 receptor signals through a novel Dok-related docking protein, Dok-R , 1998, Oncogene.

[25]  S. Orlow,et al.  Genetic mapping of a novel familial form of infantile hemangioma. , 1999, American journal of medical genetics.

[26]  Y. Masuho,et al.  Predominant expression of a receptor tyrosine kinase, TIE, in hematopoietic stem cells and B cells. , 1996, Blood.

[27]  M. Gertsenstein,et al.  Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. , 1994, Genes & development.

[28]  J. Massagué,et al.  Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway , 1999, Nature.

[29]  A. Duncan,et al.  Assignment of the endothelial-specific protein receptor tyrosine kinase gene (TEK) to human chromosome 9p21. , 1994, Genomics.

[30]  Urban Deutsch,et al.  Angiopoietin-1 induces sprouting angiogenesis in vitro , 1998, Current Biology.

[31]  F. Collins,et al.  A disease locus for hereditary haemorrhagic telangiectasia maps to chromosome 9q33–34 , 1994, Nature Genetics.

[32]  Gary R. Grotendorst,et al.  Platelet‐derived growth factor is a chemoattractant for vascular smooth muscle cells , 1982, Journal of cellular physiology.

[33]  Y. Masuho,et al.  Predominant expression of a receptor tyrosine kinase, TIE, in hematopoietic stem cells and B cells , 1996 .

[34]  G. Swarup,et al.  Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. , 1982, Biochemical and biophysical research communications.

[35]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[36]  L. Parada,et al.  Review Receptor Tyrosine Kinase Signaling in Vascular Development , 2022 .

[37]  P. D’Amore,et al.  Vascular Development: Cellular and Molecular Regulation , 2022 .

[38]  W. Risau,et al.  Molecular mechanisms of vasculogenesis and embryonic angiogenesis , 1997, Journal of cellular physiology.

[39]  J. Folkman,et al.  Blood Vessel Formation: What Is Its Molecular Basis? , 1996, Cell.

[40]  C. Heldin,et al.  B-type receptor for platelet-derived growth factor mediates a chemotactic response by means of ligand-induced activation of the receptor protein-tyrosine kinase. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[41]  K. Alitalo,et al.  Vascularization of the mouse embryo: A study of flk‐1, tek, tie, and vascular endothelial growth factor expression during development , 1995, Developmental dynamics : an official publication of the American Association of Anatomists.

[42]  Tony Pawson,et al.  Protein modules and signalling networks , 1995, Nature.